Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

ment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

Important Safety Information about PEGASYS

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may result in a worsening of cardiac disease. Ribavirin is genotoxic and mutagenic and should be considered a potential carcinogen (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

PEGASYS is contraindicated in patients with hypersensitivity to PEGASYS or any of its components, autoimmune hepatitis, and hepatic decompensation (Child-Pugh score greater than 6; class B and C) in cirrhotic CHC monoinfected patients before or during tre
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... , Aug. 22, 2014  Cannabis Science, Inc. ... formulation-based drug development and related consulting, is pleased ... international medical cannabis conference taking place at the ... , on October 22, 2014.  The multilingual ... such as researchers, health professionals, and patients, to ...
(Date:8/21/2014)...  Aptuit LLC announces that Aptuit SSCI, located ... has enhanced its capabilities in the areas of ... molecules, including biologic drugs, metabolites, and polymers, through ... spectrometer. In making the announcement, Dr. ... expanded large molecule capability enhances our early development ...
(Date:8/21/2014)...  eRelevance Corporation ( www.erelevancecorp.com ), a progressive ... has completed integration with Nextech, a popular Electronic ... Dermatology practices. "Integration allows our service ... using Nextech," stated Bob Fabbio , co-founder ... the EMR we are able to automatically target ...
Breaking Medicine Technology:Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 2Cannabis Science, Inc. (CBIS) to Sponsor 3rd International Conference on Cannabinoids in Medicine in October 2014 in Strasbourg, France 3Aptuit SSCI Adds Ultra High Resolution Q-TOF Mass Spectrometer for Large & Small Molecule Analyses 2eRelevance Corporation Integrates with Nextech Electronic Medical Records 2
... Corporation, a leading provider of powered toilet lifts for ... today a new white paper that details a return-on-investment ... financial impact of using powered toilet lifts in support ... The white paper was introduced at the 12th Annual ...
... -- Global Information Inc. is excited to announce ... 8th Annual World Health Care Congress - Europe ... healthcare systems may be diverse, but the all share many ... health systems across the entire world, and many nations are ...
Cached Medicine Technology:New White Paper Offers Model for Measuring Financial Impact of Reducing Toileting-Related Falls in Healthcare Facilities 28th Annual World Health Care Congress Set for Amsterdam, Spring 2012 2
(Date:8/22/2014)... children have a higher-than-normal risk of developing food allergies, a ... in four U.S. cities -- Baltimore, Boston, New York and ... that at least 10 percent of them developed an allergy ... most common types of food allergies were included in the ... allergies may be even higher, the researchers said. Overall, ...
(Date:8/22/2014)... severe disabilities and multiple chronic conditions are screened for ... or no chronic conditions, a new study has found. ... with moderate disabilities or women with only one chronic ... with the Li Ka Shing Knowledge Institute of St. ... often have other measures of social vulnerability, such as ...
(Date:8/22/2014)... 22, 2014 Key West Health & ... revealed their much anticipated study results of the 12 ... and released an accompanying infographic on their website. It ... have a major impact on the skin and contribute ... more. , When asked how they determined the results, ...
(Date:8/22/2014)... Until now, those with leg or foot ... to keep mobile. Thanks to an inventor from Suffolk, Va., ... , He developed a prototype for the patent-pending SUPPORT AID ... foot but provide comfort and reduce pain for those using ... is also convenient and easy to install on the crutch ...
(Date:8/22/2014)... difficulties, fainting. Each year approx. 265,000 Danes are acutely ... New research from Aarhus University and Aarhus University Hospital ... as every fourth patient are sent home again ... led to the acute hospitalisation., "Naturally, there is no ... hospital disprove that there is a serious illness. So ...
Breaking Medicine News(10 mins):Health News:Food Allergies More Common Among Inner City Kids, Study Finds 2Health News:Women with severe, chronic health issues are screened for breast cancer less often 2Health News:Key West Health & Beauty Announces The 12 Best & Worst U.S. Cities For Skin Study 2Health News:Assistive Device for Walking Invented by InventHelp Client (VBL-501) 2Health News:Many patients are discharged without a diagnosis 2
... as likely as white patients to receive therapy, study ... patients with heart disease are only half as likely ... a Duke University Medical Center study. , "This is ... associated with a 2- to 4-fold increase in the ...
... not rated high in survey , , WEDNESDAY, Oct. 29 ... not satisfied with their care, Harvard researchers report. , ... hospitals were found wanting in key areas such as ... of patients gave low ratings to pain management, and ...
... to Match Physicians with Hiring Organizations to Save You Time ... ... California (PRWEB) October 29, 2008 -- MedMatcher, Inc. today announced ... provide physicians a simple solution to find the perfect physician ...
... housing opportunities ... statewide, ... and support services professionals gathered,in Duluth for Heading Home Minnesota,s Marking ... housing,opportunities with support services for Minnesota individuals and families,who are homeless., ...
... has announced the,launch of an ongoing series of ... for managing the changing healthcare,landscape. The first in ... Pharmacy, will convene Wednesday evening,October 29, at the ... run,through Thursday, October 30, 2008., This invitation-only ...
... or not, we all experience memory errors from time to ... result of having too many other things to remember or ... have indicated that a specific type of false memory known ... a mistake that we often make when recalling a view ...
Cached Medicine News:Health News:Black Heart Patients Treated Less for Depression 2Health News:U.S. Hospitals Lag in Patient Satisfaction 2Health News:U.S. Hospitals Lag in Patient Satisfaction 3Health News:eMatchPhysicians.com Launches to Provide Physicians and Hiring Organizations with a Better Way to Find the Perfect Physician Job 2Health News:eMatchPhysicians.com Launches to Provide Physicians and Hiring Organizations with a Better Way to Find the Perfect Physician Job 3Health News:Minnesota Reaches Milestone in Goal to End Homelessness 2Health News:NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 2Health News:NovoLogix Launches First Annual Symposium for Healthcare Thought Leaders 3Health News:Our cheatin' brain: The brain's clever way of showing us the world as a whole 2
Bougie Urethrotomes for slitting the female urethra and for meatus stenosis in males...
OES Pro Optical Urethrotome...
ACMI urethrotomes are available in two distinct styles to meet your specific professional needs. The Classic Series™ Otis Urethrotome consists of a blade, straight tip, and ball tip, with an av...
... line combines market-leading optical ... durable hardware. The color-coded ... robust, ergonomic design and ... on Stryker endoscopes. The ...
Medicine Products: